June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Factors for Retreatment after Intravitreal Ranibizumab Injection for the First Treatment of Type 1 Retinopathy of Prematurity
Author Affiliations & Notes
  • Su Hwan Park
    Department of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan, Korea (the Republic of)
    Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea (the Republic of)
  • Iksoo Byon
    Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea (the Republic of)
    Biomedical Research Institute, Pusan National University Hospital, Busan, Korea (the Republic of)
  • Han Jo Kwon
    Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea (the Republic of)
    Biomedical Research Institute, Pusan National University Hospital, Busan, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Su Hwan Park None; Iksoo Byon None; Han Jo Kwon None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4917. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Su Hwan Park, Iksoo Byon, Han Jo Kwon; Factors for Retreatment after Intravitreal Ranibizumab Injection for the First Treatment of Type 1 Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4917.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal ranibizumab injection is the preferred first-line treatment for retinopathy of prematurity (ROP), but factors affecting retreatment are still ambiguous. A retrospective study was conducted to investigate the predictive factors for retreatment after the intravitreal ranibizumab injection as a first-line treatment in type 1 ROP.

Methods : The consecutive medical records of infants diagnosed with type 1 ROP from 2013 to 2021 and injected intravitreal ranibizumab 0.2 mg as the first treatment were reviewed. Only eyes with more severe ROP were included. Retreatment was performed with laser photocoagulation when ROP was reactivated. Various factors around the first injection affecting retreatment were assessed.

Results : Intravitreal ranibizumab was injected into 44 eyes of 44 infants. The mean gestational age (GA) and body weight were 27+6 weeks and 1,047 g, respectively. Retreatment was required in 21 eyes (47.7%) at an average of 8.9 weeks after the first injection at 37+1 weeks of mean GA. The retreatment group was presented with an earlier GA (26+5 vs. 28+5 weeks, p = 0.036), lower 1-minute (3.4 vs. 4.7, p = 0.014) and 5-minute (6.0 vs. 6.8, p = 0.036) Apgar scores, and more quadrants with plus sign (2.8 vs. 2.3, p = 0.044) before the injection. After the injection, the retreatment group showed a longer period of oxygen requirement (10.2 vs. 3.6 weeks, p = 0.001), late loss of plus sign (6.9 vs. 4.1 days, p = 0.014), and a longer complete involution time of ROP (18.0 vs. 12.5 weeks, p = 0.003). In multivariate logistic regression analysis (Table 1.), the risk for retreatment was increased with a lower 1-minute Apgar score (p = 0.010, OR = 2.04) and later disappearance of plus sign (p = 0.013, OR = 1.44) after the first injection.

Conclusions : About half of the type 1 ROP may need retreatment two months after the first ranibizumab injection. Delayed loss of plus sign can increase the possibility of retreatment; careful fundus examination is recommended after the first injection.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×